Despite these limitations, this is the first trial to demonstrate that low-dose nab-paclitaxel plus tislelizumab is safe and effective in elderly patients with metastatic NSCLC when used as second- or later-line treatment, even though half of the patients had a PS of 2 and many had NSCLC with EGFR/ALK variations. Here, EGFR is linked to non-small cell lung carcinoma.